What is OpenEvidence?
OpenEvidence operates as a sophisticated medical information platform, engineered to serve the rigorous demands of healthcare professionals. Born out of the Mayo Clinic Platform Accelerate program, the company leverages advanced artificial intelligence to curate and deliver high-fidelity medical insights. Its platform has earned notable validation from the New England Journal of Medicine AI, establishing it as a trusted resource for clinicians and researchers alike. By offering free and unlimited access to its services, OpenEvidence has effectively lowered the barrier to entry for evidence-based decision-making, positioning itself as an essential utility in modern clinical practice.
How much funding has OpenEvidence raised?
OpenEvidence has raised a total of $880M across 5 funding rounds:
Seed
$20M
Multiple Rounds
$610M
Series D
$250M
Seed (2021): $20M, investors not publicly disclosed
Series B (2025): $210M led by Kleiner Perkins, Thrive, Coatue, Sequoia Capital, Google, and Conviction
Other Financing Round (2025): $200M supported by Thrive Capital, Blackstone, Google, Coatue, Kleiner Perkins, and Sequoia Capital
Series C (2025): $200M featuring Sequoia Capital, Thrive Capital, GV, and Kleiner Perkins
Series D (2026): $250M backed by DST Global and Thrive Capital
Key Investors in OpenEvidence
Sequoia Capital
A premier global venture capital firm with an unparalleled track record of partnering with entrepreneurs to build market-leading companies across technology and healthcare sectors.
Thrive Capital
A New York-based investment firm that specializes in providing strategic capital to high-growth internet and software companies.
Kleiner Perkins
A Menlo Park-based venture capital firm that invests in early and growth-stage technology and life science companies, offering both capital and operational support.
What's next for OpenEvidence?
With the successful closure of its latest financing round, OpenEvidence is well-positioned to scale its operations and deepen its integration within the global healthcare infrastructure. The company's strategic roadmap likely focuses on enhancing its AI capabilities to handle increasingly complex datasets while expanding its user base among medical institutions. As it moves beyond its initial growth phase, the firm will likely prioritize the development of proprietary features that further differentiate its offering in the competitive medical technology landscape. The continued support from institutional heavyweights suggests a long-term commitment to establishing OpenEvidence as the definitive standard for medical information retrieval and analysis.
See full OpenEvidence company page
